Table 1.
Patients’ characteristics and neuroprognostic studies
| Total N = 226 |
|
|---|---|
| Female, N (%) | 102 (45) |
| Age, years, mean (SD) | 58 (17) |
| Race/ethnicity, N (%) | |
| Non-Hispanic white | 133 (59) |
| Non-Hispanic black | 56 (25) |
| Hispanic | 28 (12) |
| Other/unknown | 9 (4) |
| Arrest location, N (%) | |
| Out of hospital | 139 (62) |
| Emergency department | 19 (8) |
| In hospital | 68 (30) |
| Arrest rhythm, N (%) | |
| VF/VT | 45 (20) |
| Pulseless electrical activity | 112 (50) |
| Asystole | 53 (23) |
| Unknown | 16 (7) |
| TTM, N (%) | 136 (60) |
| Target temperature 32–34°C | 95 (70) |
| Target temperature 36°C | 41 (30) |
| Neuroprognostic study, N (%) | |
| EEG | 197 (87) |
| SSEP, days 1–5 | 43 (19) |
| NSE, days 1–3 | 45 (20) |
| Head CT, ≤24h | 180 (80) |
| Brain MRI, days 2–6 | 96 (42) |
| Survival to discharge, N (%) | 81 (36) |
| CPC score 1 | 15 (7) |
| CPC score 2 | 9 (4) |
| CPC score 3 | 42 (19) |
| CPC score 4 | 15 (7) |
| Hospital progression to brain death, N (%) | 26 (12) |
| Days to brain death, median (IQR) | 4 (2–6) |
| Hospital progression to cardiac death, N (%) | 7 (3) |
| Days to cardiac death, median (IQR) | 4 (2–29) |
| WLST, N (%) | 118 (52) |
| WLST day, median (IQR) | 6 (4–12) |
| 6-month outcome, N (%) | |
| CPC score 1 | 21 (10) |
| CPC score 2 | 12 (5) |
| CPC score 3 | 29 (13) |
| CPC score 4 | 7 (3) |
| CPC score 5 | 157 (69) |
Abbreviations: VF/VT = ventricular fibrillation/ventricular tachycardia; TTM = targeted temperature management; SSEP = somatosensory evoked potential; NSE = neuron specific enolase; CPC = Cerebral Performance Category; IQR = interquartile range; WLST = withdrawal of life-sustaining therapies